Synthesis of a Novel 9-O Berberine Derivative and Evaluation of Its Hypoglycemic Effect
Author:
Gladkova Elizaveta D.12ORCID, Valutsa Nicolae2, Borisov Sergey A.1ORCID, Khvostov Mikhail V.1ORCID, Luzina Olga A.1ORCID, Tolstikova Tatiana G.1, Salakhutdinov Nariman F.1
Affiliation:
1. N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia 2. Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
Abstract
Berberine is a phytogenic isoquinoline alkaloid which demonstrates several pharmacological effects, including a hypoglycemic effect. Its medical use is limited by its very low bioavailability. Synthesizing new berberine derivatives might help in overcoming this problem. In this work, we report on the synthesis and biological evaluation of a novel berberine 9-O-derivative. At an oral dose of 25 mg/kg, the compound demonstrated hypoglycemic activity in an oral glucose tolerance test performed using C57BL/6 mice.
Funder
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS
Subject
Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry
Reference12 articles.
1. Xia, X., Yan, J., Shen, Y., Tang, K., Yin, J., Zhang, Y., Yang, D., Liang, H., Ye, J., and Weng, J. (2011). Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. PLoS ONE, 6. 2. Synthesis and antihyperglycemic evaluation of various protoberberine derivatives;Bian;Bioorg. Med. Chem. Lett.,2006 3. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways;Dou;Biomed. Pharmacother.,2021 4. Structure-activity relationship of berberine derivatives for their glucose-lowering activities;Ren;Int. J. Clin. Exp. Med.,2017 5. Khvostov, M.V., Gladkova, E.D., Borisov, S.A., Fedotova, M.S., Zhukova, N.A., Marenina, M.K., Meshkova, Y.V., Valutsa, N., Luzina, O.A., and Tolstikova, T.G. (2023). 9-N-n-alkyl Berberine Derivatives: Hypoglycemic Activity Evaluation. Pharmaceutics, 15.
|
|